SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-098282
Filing Date
2021-07-30
Accepted
2021-07-30 16:31:54
Documents
12
Period of Report
2021-07-28
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2123737d1_8k.htm   iXBRL 8-K 58878
  Complete submission text file 0001104659-21-098282.txt   234594

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nbrv-20210728.xsd EX-101.SCH 3185
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbrv-20210728_lab.xml EX-101.LAB 34593
4 XBRL PRESENTATION FILE nbrv-20210728_pre.xml EX-101.PRE 22710
5 EXTRACTED XBRL INSTANCE DOCUMENT tm2123737d1_8k_htm.xml XML 3636
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 211133013
SIC: 2834 Pharmaceutical Preparations